Our Pipeline
Our diverse pipeline is designed to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable.
Our diverse pipeline is designed to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable.
| Product Candidate | Target | Indication | Discovery | Preclinical | IND/CTA | Phase 1 | Phase 2 | Phase 3 | Filing | Approval/ EUA |
| AdimFlu-S (QIS)(1) |
Quadrivalent
Influenza A and B |
Seasonal Influenza | China | |||||||
| SCB-2019 (CpG 1018/Alum)(2) | SARS-CoV-2 S-Trimer (Broad Neutralization) |
COVID-19 |
China Global (Ex-China) |
|||||||
| SCB-1019 | RSV F-trimer | Respiratory Syncytial Virus (RSV) | ||||||||
| SCB-2023B |
XBB.1.5-Adapted
SARS-CoV-2 S-Trimer |
COVID-19 | ||||||||
| SCB-1001 | Rabies G-Trimer | Rabies |
| Product Candidate | Target | Indication | Discovery | Preclinical | IND/CTA | Phase 1 | Phase 2 | Phase 3 | Filing | Approved/ EUA |
| SCB-219M(3) | TPO Mimetic Bispecific-Fc | Chemotherapy-Induced Thrombocytopenia (CIT) | ||||||||
| SCB-313(4) | TRAIL-Trimer | Intracavitary Malignancies (Malignant Ascites, Malignant Pleural Effusions, Peritoneal Carcinomatosis) |
(1) Clover entered into an exclusive agreement with Adimmune to commercialize AdimFlu-S (QIS) in mainland China in February 2023.
(2) COVID-19 vaccine received EUA in China in December 2022.
(3) Received positive Phase I results for SCB-219M, a Phase Ib trial evaluating repeated dosing of SCB-219M in CIT and CTIT patients is planned to initiate in 2024.
(4) Oncology product candidate for the treatment of malignant ascites (MA), malignant pleural effusions (MPE), and peritoneal carcinomatosis (PC) to address global unmet medical need of intracavitary malignancies. Five Phase 1 trials completed in China and Australia. Continued internal development of SCB-313 has been paused and pending further assessment of development strategy and resource allocation.
AdimFlu-S (QIS) is a quadrivalent split inactivated vaccine intended for use in the prevention of influenza. AdimFlu-S (QIS) was approved by the China National Medical Products Administration in January 2022 for individuals aged three years and older.
Clover received Emergency Use Authorization (EUA) for SCB-2019 (CpG 1018/Alum) in China, and it was selected as the recommended vaccine in the "Implementation Plan for the Second Dose of Enhanced Immunization of COVID-19 Vaccine”.
Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus, and combined it with Dynavax's CpG 1018 advanced adjuvant and aluminum hydroxide (alum). Phase 2/3 data from 30,000+ participants across five countries showed that SCB-2019 (CpG 1018/Alum) achieved 100% efficacy against severe COVID-19 and hospitalization caused by all strains of SARS-CoV-2 circulating during the trial, and a potentially best-in-field safety profile. To date, these trials have shown that SCB-2019 (CpG 1018/Alum) elicited a robust neutralization of variants including Omicron.
Clover also developed XBB-Adapted SARS-CoV-2 vaccine candidate SCB-2023B based on the Trimer-Tag technology platform, and made a rolling regulatory submission to the Chinese regulatory authorities for this vaccine candidate.
SCB-1019 is a bivalent RSV-A/RSV-B vaccine candidate based on the prefusion-stabilized F (PreF) protein leveraging the validated Trimer-Tag platform and proprietary stabilizing PreF mutations.
In December 2023, Clover initiated a phase I clinical trial for SCB-1019, which made Clover the first vaccine company based in China developing an RSV vaccine based on stabilized PreF to enter the clinical trial stage. Safety and immunogenicity results are expected by the second half of 2024.
The R&D development on Clover’s self developed rabies vaccine candidate SCB-1001 leveraging the Trimer-Tag platform is ongoing.
SCB-219M is an innovative thrombopoietin receptor agonist (TPO-RA) mimetic bispecific Fc-fusion protein, for the treatment of cancer patients with chemotherapy-induced thrombocytopenia (CIT).
We have announced positive Phase Ⅰ results for SCB-219M. A Phase Ⅰb trial evaluating repeated dosing of SCB-219M in CIT and CTIT patients is planned to initiate in 2024.
We developed SCB-313 as a covalently-linked, native-like trimeric fusion protein which is structurally and functionally differentiated from the dimeric antibody-based structures and other native ligand-based candidates targeting this pathway. We believe SCB-313 has the potential to address the unmet global need for the treatment of intracavitary malignancies, including malignant ascites, malignant pleural effusions and peritoneal carcinomatosis.
